Assembly Biosciences (NASDAQ:ASMB) Posts Quarterly Earnings Results

Assembly Biosciences (NASDAQ:ASMB) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.57) EPS for the quarter, beating analysts’ consensus estimates of ($2.12) by $0.55, Zacks reports. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%.

Assembly Biosciences Stock Performance

Assembly Biosciences stock traded down $0.16 during midday trading on Thursday, reaching $10.69. 5,938 shares of the stock were exchanged, compared to its average volume of 24,351. The company’s fifty day moving average is $13.13 and its 200-day moving average is $15.21. Assembly Biosciences has a 52 week low of $10.27 and a 52 week high of $19.93.

Insider Activity at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of the stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the purchase, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.